Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

NCT05093322 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT05093322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05093322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Lead sponsor
Hutchmed
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2021
Completion date
April 25, 2023
Enrollment
13 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, lymphoma, non-rhabdomyosarcoma soft tissue sarcoma (nrsts), osteosarcoma, rhabdomyosarcoma, solid tumor